Patient Focus

March 12, 2021 Decades of Pain and Uncertainty: Donna’s AHP Story For more than 20 years, Donna navigated debilitating pain, mysterious symptoms and uncertainty about her health. Today, with a better handle on her wellbeing Read More ›
March 2, 2021 When Are Kidney Stones a Red Flag? According to some estimates, every 1 in 10 adults in the U.S. experiences a kidney stone, suggesting that kidney stones can be rather prevalent. But when are st Read More ›
February 23, 2021 Rare Disease Day 2021: Rare Is Many. Rare Is Strong. Rare Is Proud. While some aspects of living with a rare disease are similar, there is no singular shared experience. There is, however, a common sentiment among those impacted Read More ›
December 7, 2020 Alnylam Releases 2nd Annual Patient Access Philosophy Report The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics. Read More ›
November 5, 2020 My Journey to an AHP Diagnosis: Claire and Candace Claire and Candace share their stories of their long journeys to an acute hepatic porphyria (AHP) diagnosis. Read More ›
September 14, 2020 Navigating AHP and Pain During a Pandemic As the COVID-19 pandemic continues to have a significant impact on people and communities around the world, it poses unique challenges for people living with AH Read More ›
August 3, 2020 How to Evaluate a Medicine for the Treatment of an Ultra-rare Disease Such as PH1 For a new medicine to become available, it needs to undergo stringent testing in clinical trials to evaluate its safety and, importantly, its efficacy (how well Read More ›
June 2, 2020 Announcing the 2019-2020 Advocacy for Impact Grant Recipients The Alnylam 2019-2020 Advocacy for Impact grant recipients come from five countries across three continents, and will receive grants totaling USD $270,000.00... Read More ›
May 6, 2020 Navigating the Winding Road to Drug Approvals Learn about the winding road and key members involved in getting a new drug approved. Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site